1. Home
  2. AIG vs ARGX Comparison

AIG vs ARGX Comparison

Compare AIG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIG
  • ARGX
  • Stock Information
  • Founded
  • AIG 1919
  • ARGX 2008
  • Country
  • AIG United States
  • ARGX Netherlands
  • Employees
  • AIG N/A
  • ARGX N/A
  • Industry
  • AIG Life Insurance
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AIG Finance
  • ARGX Health Care
  • Exchange
  • AIG Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • AIG 43.9B
  • ARGX 51.1B
  • IPO Year
  • AIG N/A
  • ARGX 2017
  • Fundamental
  • Price
  • AIG $78.60
  • ARGX $895.51
  • Analyst Decision
  • AIG Buy
  • ARGX Strong Buy
  • Analyst Count
  • AIG 12
  • ARGX 17
  • Target Price
  • AIG $89.55
  • ARGX $872.12
  • AVG Volume (30 Days)
  • AIG 3.8M
  • ARGX 376.6K
  • Earning Date
  • AIG 11-04-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • AIG 2.30%
  • ARGX N/A
  • EPS Growth
  • AIG N/A
  • ARGX N/A
  • EPS
  • AIG 5.51
  • ARGX 23.27
  • Revenue
  • AIG $27,120,000,000.00
  • ARGX $3,683,281,000.00
  • Revenue This Year
  • AIG $2.94
  • ARGX $85.93
  • Revenue Next Year
  • AIG $2.27
  • ARGX $35.17
  • P/E Ratio
  • AIG $14.21
  • ARGX $35.72
  • Revenue Growth
  • AIG 2.52
  • ARGX 92.98
  • 52 Week Low
  • AIG $69.24
  • ARGX $510.06
  • 52 Week High
  • AIG $88.07
  • ARGX $907.47
  • Technical
  • Relative Strength Index (RSI)
  • AIG 49.98
  • ARGX 77.86
  • Support Level
  • AIG $75.46
  • ARGX $812.79
  • Resistance Level
  • AIG $77.49
  • ARGX $907.47
  • Average True Range (ATR)
  • AIG 1.87
  • ARGX 25.22
  • MACD
  • AIG -0.04
  • ARGX 4.28
  • Stochastic Oscillator
  • AIG 45.35
  • ARGX 93.00

About AIG American International Group Inc. New

American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: